MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAIA MAIA Biotechnology Inc.

Not Yet Opened 09-03 16:00:00 EDT

1.33

-0.04

-2.92%

盘后1.36

+0.03+2.26%

19:58 EDT

High1.40	Low1.31	Vol469.18K
Open1.38	D1 Closing1.37	Amplitude6.57%
Mkt Cap80.69M	Tradable Cap73.95M	Total Shares60.67M
T/O626.26K	T/O Rate0.84%	Tradable Shares55.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":1.33,"timestamp":1788465600000,"preClose":1.37,"halted":0,"volume":469181,"hourTrading":{"tag":"盘后","latestPrice":1.36,"preClose":1.33,"latestTime":"19:58 EDT","volume":5300,"amount":7135.6289,"timestamp":1788479930645,"change":0.03,"changeRate":0.022556,"amplitude":0.022556},"delay":0,"changeRate":-0.029197080291970826,"floatShares":55605100,"shares":60671491,"eps":-0.608478,"marketStatus":"Not Yet Opened","change":-0.04,"latestTime":"09-03 16:00:00 EDT","open":1.38,"high":1.4,"low":1.31,"amount":626260.5467312001,"amplitude":0.065693,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.608478,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788508800000},"marketStatusCode":0,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":1.37,"preHourTrading":{"tag":"盘前","latestPrice":1.36,"preClose":1.37,"latestTime":"09:19 EDT","volume":997,"amount":1375.4543207,"timestamp":1788441567047,"change":-0.01,"changeRate":-0.007299,"amplitude":0.029197},"postHourTrading":{"tag":"盘后","latestPrice":1.36,"preClose":1.33,"latestTime":"19:58 EDT","volume":5300,"amount":7135.6289,"timestamp":1788479930645,"change":0.03,"changeRate":0.022556,"amplitude":0.022556},"volumeRatio":1.127684},"requestUrl":"/m/hq/s/MAIA/tweets","defaultTab":"tweets","newsList":[{"id":"2664486983","title":"Maia Bio Director Ramiro Guerrero Buys 133,790 Shares Worth $185,114.90","url":"https://stock-news.laohu8.com/highlight/detail?id=2664486983","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664486983?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:17","pubTimestamp":1788293820,"startTime":"0","endTime":"0","summary":"Maia Bio director Ramiro Guerrero buys 133,790 shares worth $185,114.90Maia Biotechnology director Ramiro Guerrero bought 133,790 shares of common stock at prices ranging from $1.35 to $1.39.Guerrero’","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL1zPgtm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maia Bio Director Ramiro Guerrero Buys 133,790 Shares Worth $185,114.90","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662871655","title":"Maia Bio Director Ramiro Guerrero Acquires 1,794 Common Shares Worth $2,386.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2662871655","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662871655?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:57","pubTimestamp":1787745449,"startTime":"0","endTime":"0","summary":"Maia Bio director Ramiro Guerrero acquires 1,794 common shares worth $2,386.02Maia Biotechnology director Ramiro Guerrero bought 1,794 common shares at USD 1.33 each, a Form 4 filing shows.Guerrero’s ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL1dJ83B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maia Bio Director Ramiro Guerrero Acquires 1,794 Common Shares Worth $2,386.02","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662063862","title":"Maia Biotechnology Director Ramiro Guerrero Reports Purchase of 11,899 Common Shares for $16,301.63","url":"https://stock-news.laohu8.com/highlight/detail?id=2662063862","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662063862?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:10","pubTimestamp":1787602240,"startTime":"0","endTime":"0","summary":"Maia Biotechnology director Ramiro Guerrero reports purchase of 11,899 common shares for $16,301.63Maia Biotechnology director Ramiro Guerrero bought 11,899 common shares in open-market purchases at U","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL4q7JKZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maia Biotechnology Director Ramiro Guerrero Reports Purchase of 11,899 Common Shares for $16,301.63","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661229712","title":"MAIA Biotechnology files $150M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2661229712","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661229712?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:20","pubTimestamp":1787343608,"startTime":"0","endTime":"0","summary":"16:17 EDT MAIA Biotechnology (MAIA) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-files-150m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-files-150m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931393","title":"MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931393","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931393?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:06","pubTimestamp":1786367179,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 27.78 percent increase over losses of $(0.18) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61073843/maia-biotechnology-q2-eps-0-13-misses-0-11-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658193906","title":"Maia Biotech Q2 FY26 Net Loss Widens 49% to $7.94 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658193906","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658193906?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:02","pubTimestamp":1786366976,"startTime":"0","endTime":"0","summary":"Maia Biotech Q2 FY26 net loss widens 49% to $7.94 millionMaia Biotechnology posted a net loss of $7.94 million in Q2 2026, widening 49% from a year earlier.Operating loss widened 61% to $8.32 million ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLbh97S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650979881","title":"Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650979881","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650979881?lang=en_us&edition=fundamental","pubTime":"2026-07-10 01:45","pubTimestamp":1783619124,"startTime":"0","endTime":"0","summary":"In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc., with a price target of $14.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-their-buy-rating-for-maia-biotechnology-inc-maia-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-their-buy-rating-for-maia-biotechnology-inc-maia-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBL","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649947429","title":"Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr in 3l Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2649947429","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649947429?lang=en_us&edition=fundamental","pubTime":"2026-07-08 22:49","pubTimestamp":1783522190,"startTime":"0","endTime":"0","summary":"July 8 (Reuters) - Maia Biotechnology Inc::*MAIA BIOTECHNOLOGY REPORTS STRONG INITIAL EFFICACY DATA IN THIRD-LINE NON-SMALL CELL LUNG CANCER FROM PHASE 2 THIO-101 PART C EXPANSION TRIAL*MAIA BIOTECHNO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nRSD7qCsFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649619991","title":"MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2649619991","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649619991?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:50","pubTimestamp":1783518622,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) announced initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-reports-efficacy-data-from-phase-2-thio-101-part-c-expansion-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-reports-efficacy-data-from-phase-2-thio-101-part-c-expansion-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA","GDOC","IDNA","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649999043","title":"Maia Biotech Reports 90.5% Disease Control Rate in Phase 2 Third-line NSCLC Trial Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2649999043","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649999043?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:45","pubTimestamp":1783518318,"startTime":"0","endTime":"0","summary":"Maia Biotech reports 90.5% disease control rate in Phase 2 third-line NSCLC trial expansionMaia Biotechnology reported a 90.5% interim disease control rate in Phase 2 THIO-101 Part C for third-line ad","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL19MYzw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4588","LU2210150020.SGD","SG9999014039.USD","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD","MAIA","BCDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649999064","title":"Maia Biotechnology - Ateganosine Plus Cemiplimab Shows Acceptable Safety Profile in Heavily Pre-treated Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2649999064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649999064?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:45","pubTimestamp":1783518300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUAQ7RJ8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649990619","title":"Maia Biotechnology Reports Strong Initial Efficacy Data in Third-line Non-small Cell Lung Cancer from Phase 2 Thio-101 Part C Expansion Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2649990619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649990619?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:45","pubTimestamp":1783518300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUAQ7RJ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649799906","title":"Maia Biotechnology - Thio-101 Part C Shows 90.5% Disease Control Rate in 3L Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2649799906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649799906?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:45","pubTimestamp":1783518300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUAQ7RJ8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649062999","title":"Maia Biotechnology - Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr in 3L Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2649062999","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649062999?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:45","pubTimestamp":1783518300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUAQ7RJ8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646605870","title":"Maia Biotechnology Completes International Enrollment in Part C of Phase 2 Thio-101 Expansion Trial in Third-line Non-small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646605870","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646605870?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:08","pubTimestamp":1782389280,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA5MLKGH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646870966","title":"MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646870966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646870966?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:08","pubTimestamp":1782389280,"startTime":"0","endTime":"0","summary":"Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June  25, 2026  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317503/0/en/MAIA-Biotechnology-Completes-International-Enrollment-in-Part-C-of-Phase-2-THIO-101-Expansion-Trial-in-Third-Line-Non-Small-Cell-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0210528500.USD","BK4139","BK4107","MAIA","L","ORR","BK4585","CPI","LU2487616109.SGD","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644810085","title":"Maia Biotech opens enrollment at Emory Winship for Phase 2 ateganosine NSCLC trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644810085","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644810085?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:31","pubTimestamp":1781785888,"startTime":"0","endTime":"0","summary":"Maia Biotechnology opened enrollment at Emory University’s Winship Cancer Institute for its Phase 2 THIO-101 expansion trial in third-line NSCLC.The study evaluates ateganosine, a telomere-targeting agent, followed by cemiplimab in patients resistant to checkpoint inhibitors and chemotherapy.Early results from Parts A and B have already been presented, showing encouraging clinical benefit in some patients.The U.S. expansion adds a third domestic site, supporting broader recruitment for a setting with no FDA-approved third-line options.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbNrbBV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","BK4588","BK4112","IE00B64PRP62.GBP","SG9999014021.USD","MAIA","LU2210149790.SGD","BK4585","SG9999014013.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644808302","title":"Maia Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University","url":"https://stock-news.laohu8.com/highlight/detail?id=2644808302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644808302?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:30","pubTimestamp":1781785800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nTUABM17DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167022508","title":"Compugen to Unveil Latest Data from MAIA Ovarian Cancer Drug Trial at European Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1167022508","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167022508?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:20","pubTimestamp":1781191233,"startTime":"0","endTime":"0","summary":"Clinical-stage cancer immunotherapy company Compugen Ltd. announced on Thursday that it will present the latest progress from its MAIA-ovarian trial in a poster presentation at the 2026 European...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442946","title":"Maia Biotech opens enrollment at second US site for Phase 2 THIO-101 lung cancer trial expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442946","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642442946?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:20","pubTimestamp":1781097631,"startTime":"0","endTime":"0","summary":"Maia Biotechnology opened enrollment at a second US site for its Phase 2 THIO-101 expansion trial in third-line non-small cell lung cancer.No new results were presented; additional expansion data are expected in future interim updates to support a potential FDA accelerated approval filing.The study evaluates ateganosine in patients who failed checkpoint inhibitors and chemotherapy, aiming to show clinically meaningful benefit without detailing metrics.Maia is also screening patients for a pivotal Phase 3 overall-survival study comparing ateganosine sequenced with a CPI versus investigator’s-choice chemotherapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL6MN2LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.MAIABiotech.com","stockEarnings":[{"period":"1week","weight":-0.0362},{"period":"1month","weight":-0.0221},{"period":"3month","weight":-0.0221},{"period":"6month","weight":-0.1364},{"period":"1year","weight":-0.1192},{"period":"ytd","weight":-0.1307}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.285723},{"month":2,"riseRate":0,"avgChangeRate":-0.06082},{"month":3,"riseRate":0.25,"avgChangeRate":-0.026788},{"month":4,"riseRate":0.5,"avgChangeRate":0.130553},{"month":5,"riseRate":0.75,"avgChangeRate":0.111873},{"month":6,"riseRate":0.5,"avgChangeRate":-0.089611},{"month":7,"riseRate":0.25,"avgChangeRate":-0.076547},{"month":8,"riseRate":0.2,"avgChangeRate":-0.109363},{"month":9,"riseRate":0.4,"avgChangeRate":0.003122},{"month":10,"riseRate":0.25,"avgChangeRate":-0.039628},{"month":11,"riseRate":0.25,"avgChangeRate":-0.189158},{"month":12,"riseRate":0.5,"avgChangeRate":0.077797}],"exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction